2026-04-09
Parkinson’s disease: how can off periods be better controlled?
Neurology
By Ana Espino | Published on April 9, 2026 | 4 min read
Parkinson’s disease is a chronic neurodegenerative disorder characterized by the progressive worsening of motor symptoms. As the disease advances, a large majority of patients treated with levodopa develop motor fluctuations, marked by unpredictable alternations between “ON” and “OFF” periods. These fluctuations lead to significant clinical variability, have a lasting impact on quality of life, and complicate therapeutic management.
Despite major therapeutic advances, controlling these fluctuations remains a significant challenge. Current strategies rely on optimizing dopaminergic treatments and introducing targeted adjunctive therapies. However, the growing number of available options, combined with the lack of a clear hierarchy based on robust evidence, makes therapeutic decision-making particularly complex in clinical practice.
In this context, this international review provides a structured update of evidence-based recommendations for managing motor fluctuations in Parkinson’s disease. It aims to critically assess the efficacy, tolerability, and clinical relevance of different therapeutic strategies in order to guide more rational and personalized care.
This systematic review is based on the analysis of 102 randomized controlled trials, selected using strict criteria including patients on levodopa experiencing motor fluctuations. Data were evaluated using a methodology inspired by GRADE, incorporating both the quality of evidence and the clinical relevance of outcomes.
The results show that several treatments are considered effective, including certain extended-release formulations of levodopa, dopamine agonists (pramipexole, ropinirole, rotigotine), as well as agents such as opicapone and safinamide. These interventions significantly reduce OFF time—often by more than one hour per day—while increasing ON time without dyskinesia.
More advanced approaches, such as subthalamic nucleus deep brain stimulation (STN-DBS), demonstrate major efficacy, with marked improvement in motor symptoms, increased ON time, and enhanced quality of life.
Other treatments are considered probably effective, including continuous infusions of levodopa or apomorphine, as well as certain classes such as COMT inhibitors and MAO-B inhibitors. These options provide clinical benefits, although with more limited levels of evidence or consistency.
Conversely, several interventions show insufficient evidence—or no demonstrated efficacy—highlighting the heterogeneity of therapeutic responses. The findings also underscore substantial variability in treatment effects and a limited impact on certain outcomes, particularly quality of life.
Parkinson’s disease, characterized by complex motor fluctuations, requires continuous adaptation of therapeutic strategies. This review confirms that multiple options can significantly reduce OFF time, while also emphasizing the complexity of treatment selection in clinical practice.
Overall, treatment optimization appears effective, with options ranging from oral therapies to invasive approaches. However, several limitations remain, including significant heterogeneity among studies, a lack of robust head-to-head comparisons between strategies, and insufficient long-term data.
Future perspectives rely on a more targeted approach, integrating the patient’s clinical profile, disease stage, and individual expectations. The development of comparative studies and new therapeutic approaches may pave the way for more personalized medicine, ultimately improving long-term management of motor fluctuations.
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
Parkinson’s disease is a chronic neurodegenerative disorder characterized by the progressive worsening of motor symptoms. As the disease advances, a large majority of patients treated with levodopa develop motor fluctuations, marked by unpredictable alternations between “ON” and “OFF” periods. These fluctuations lead to significant clinical variability, have a lasting impact on quality of life, and complicate therapeutic management.
Despite major therapeutic advances, controlling these fluctuations remains a significant challenge. Current strategies rely on optimizing dopaminergic treatments and introducing targeted adjunctive therapies. However, the growing number of available options, combined with the lack of a clear hierarchy based on robust evidence, makes therapeutic decision-making particularly complex in clinical practice.
In this context, this international review provides a structured update of evidence-based recommendations for managing motor fluctuations in Parkinson’s disease. It aims to critically assess the efficacy, tolerability, and clinical relevance of different therapeutic strategies in order to guide more rational and personalized care.
Which treatments truly reduce OFF time?
This systematic review is based on the analysis of 102 randomized controlled trials, selected using strict criteria including patients on levodopa experiencing motor fluctuations. Data were evaluated using a methodology inspired by GRADE, incorporating both the quality of evidence and the clinical relevance of outcomes.
The results show that several treatments are considered effective, including certain extended-release formulations of levodopa, dopamine agonists (pramipexole, ropinirole, rotigotine), as well as agents such as opicapone and safinamide. These interventions significantly reduce OFF time—often by more than one hour per day—while increasing ON time without dyskinesia.
More advanced approaches, such as subthalamic nucleus deep brain stimulation (STN-DBS), demonstrate major efficacy, with marked improvement in motor symptoms, increased ON time, and enhanced quality of life.
Other treatments are considered probably effective, including continuous infusions of levodopa or apomorphine, as well as certain classes such as COMT inhibitors and MAO-B inhibitors. These options provide clinical benefits, although with more limited levels of evidence or consistency.
Conversely, several interventions show insufficient evidence—or no demonstrated efficacy—highlighting the heterogeneity of therapeutic responses. The findings also underscore substantial variability in treatment effects and a limited impact on certain outcomes, particularly quality of life.
Personalizing treatment to better control Parkinson’s disease
Parkinson’s disease, characterized by complex motor fluctuations, requires continuous adaptation of therapeutic strategies. This review confirms that multiple options can significantly reduce OFF time, while also emphasizing the complexity of treatment selection in clinical practice.
Overall, treatment optimization appears effective, with options ranging from oral therapies to invasive approaches. However, several limitations remain, including significant heterogeneity among studies, a lack of robust head-to-head comparisons between strategies, and insufficient long-term data.
Future perspectives rely on a more targeted approach, integrating the patient’s clinical profile, disease stage, and individual expectations. The development of comparative studies and new therapeutic approaches may pave the way for more personalized medicine, ultimately improving long-term management of motor fluctuations.
Read next: Gene therapy: a turning point for parkinson’s disease?
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
Last press reviews
Vitamin D and the microbiome: toward immune reprogramming in ibd
By Elodie Vaz | Published on April 10, 2026 | 3 min read<br><br><br>...
Animal allergies: what if your diagnosis is wrong?
By Ana Espino | Published on April 10, 2026 | 3 min read<br><br>
Parkinson’s disease: how can off periods be better controlled?
By Ana Espino | Published on April 9, 2026 | 4 min read<br><br><br>